ReviewHistology and histopathology2026
Osteofibrous dysplasia (OFD) and adamantinoma: A comprehensive review and updates.
Review in Histology and histopathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Management of Tibial Adamantinoma: Balancing Oncologic Cure and Reconstructive Longevity.Cureus · 2026Review
- Article
- Motorized Intramedullary Bone Transport Nail for Reconstruction of a Large Diaphyseal Bone Defect after Tumor Resection in a Child-A Case Report.Children (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteofibrous dysplasia (OFD) and adamantinoma constitute rare bone tumors. Currently, the World Health Organization (WHO) classification of soft tissue and bone tumors stratifies adamantinoma into three main subtypes, namely OFD-like adamantinoma, classic adamantinoma, including its various growth patterns, and an extremely uncommon subtype, dedifferentiated adamantinoma. Given the wide clinicopathological spectrum of adamantinoma, several tumors constitute the differential diagnoses. An exact diagnosis in these scenarios has significant treatment-related implications, such as synovial sarcoma vs. spindle cell-type adamantinoma, and metastatic sarcomatoid carcinoma vs. adamantinoma, to name but a few. There have been studies attempting to explore the proximity/relationship between OFD, OFD-like adamantinoma, and classic adamantinoma. This review focuses on the clinical, radiological, and pathological features of OFD, as well as the histopathological spectrum of adamantinoma, including its updates and various subtypes and tumors that constitute its differential diagnosis.
Indexed as
Identifiers
40539236What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.